Sales rose 34% to $458 million in the first nine months of 2023 from its use as a second-line or later treatment for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs), a ...

The advent of targeted radiopharmaceuticals is revolutionising the field of oncology. These innovative therapies integrate systemically delivered radiotherapy into diagnostic and personalised ...

While the emergence of immune checkpoint inhibitors has improved cancer patient outcomes ... efficacy and safety of treatment of gastroenteropancreatic neuroendocrine neoplasms with regorafenib ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

A new multicenter study by researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with the National Cancer Institute-funded Clinical Proteomic Tumor Analysis Consortium (CPTAC) ...

Mar. 13, 2025 — A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States ...

15, 2025 — Bacteria naturally present in the human intestine (known as the gut microbiota) can transform cholesterol-derived bile acids into powerful metabolites that strengthen anti-cancer ...

The approval for use in advanced neuroendocrine tumors is supported by data from the phase 3 CABINET trial (ClinicalTrials.gov Identifier: NCT03375320). The double-blind, placebo-controlled study ...